What Makes Icon PLC (ICLR) an Investment Bet?
GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets had a difficult start to 2025; with high levels of volatility in all of the main indices. The Value Fund finished the first quarter +3.0% net of fees and expenses net of fees and expenses. For the first quarter, the S&P/TSX retuned +1.5%, the S&P500 -4.2% and the Nasdaq –10.2%. The markets fell around 10% this past week as a result of President Trump's April 2 "Liberation Day" tariff announcement. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025.
In its first quarter 2025 investor letter, GreensKeeper Asset Management emphasized stocks such as ICON Public Limited Company (NASDAQ:ICLR). Headquartered in Dublin, Ireland, ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization. The one-month return of ICON Public Limited Company (NASDAQ:ICLR) was -13.11%, and its shares lost 50.23% of their value over the last 52 weeks. On April 9, 2025, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $155.49 per share with a market capitalization of $12.567 billion.
GreensKeeper Asset Management stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2025 investor letter:
"We made one new purchase in the quarter: ICON Public Limited Company (NASDAQ:ICLR). ICLR is a leading contract research organization (CRO) based in Ireland that manages clinical trials for pharmaceutical and biotechnology companies worldwide. Despite some uncertainty driven by recent personnel changes at the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), we believe that new drugs and medical devices will continue to be developed, and scientific progress will continue. New drugs require rigorous clinical testing before reaching the market. As a leading CRO, ICLR will capture its fair share of clinical trials once the dust settles."
A laboratory setting with a team of scientists working on a clinical trial.
ICON Public Limited Company (NASDAQ:ICLR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 46 hedge fund portfolios held ICON Public Limited Company (NASDAQ:ICLR) at the end of the fourth quarter which was 48 in the previous quarter. ICON Public Limited Company's (NASDAQ:ICLR) fourth quarter revenue was $2.04 billion, represents a year-on-year decrease of 1.2%. While we acknowledge the potential of ICON Public Limited Company (NASDAQ:ICLR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
We covered ICON Public Limited Company (NASDAQ:ICLR) in another article, where we shared LVS Advisory's views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Feds seek to ditch settlement over alleged redlining with North Jersey bank
The Trump administration is asking a judge to drop a 2022 settlement the Justice Department had reached with North Jersey-based Lakeland Bank — which was later absorbed by Provident Bank — over allegations of redlining against Black and Hispanic customers. While Provident Bank said it will continue to provide low-cost mortgages to underserved communities, the motion by the U.S. Justice Department to abandon the settlement has drawn the ire of community advocates and legal experts, who say it would make it easier for banks to engage in redlining. 'It goes without saying it's a good thing when financial institutions are complying with those consent orders, but when you take away the teeth — the actual enforcement — who's to say that they will continue to comply,' said Leila Amirhamzeh, director of community reinvestment for New Jersey Citizen Action, a consumer advocacy four-page motion by the Justice Department, filed May 28 in U.S. District Court, seeks to terminate the consent order the Biden administration negotiated with what was then Lakeland Bank. In the initial complaint, the Justice Department said Lakeland violated the federal Fair Housing Act and Equal Credit Opportunity Act by deliberately avoiding banking with Black and Hispanic customers, particularly in and around Newark. The discrimination in question allegedly took place between 2015 and 2021, according to the Biden administration. To settle the complaint, Lakeland agreed to pay $12 million to subsidize mortgages, home improvement loans and home refinancing loans for Black and Hispanic residents and open two branches in underserved neighborhoods. Lakeland also had to provide $150,000 a year for advertising, outreach and consumer finance education in the Newark area. Newark Mayor and Democratic gubernatorial candidate Ras Baraka wanted one of those new branches to be in his city, and the Greater Toms River Chamber of Commerce also wanted a branch in its area. According to the Provident Bank website, there are currently four locations in Newark and three in Toms River. After acquiring Lakeland, Provident took ownership of the settlement and the mandate to open two branches in underserved areas of New Jersey. The Justice Department in its motion to terminate the order said Lakeland reached substantial commitment to comply with the consent agreement and it is committed to continuing its disbursement of the loan subsidy. Provident spokesperson Keith Buscio told and the USA TODAY Network New Jersey that the bank remains committed to the loan subsidy initiative. He said Provident is not a party to the litigation and referred other questions to the Justice Department. The Justice Department could not immediately be reached for comment. Baraka's office in Newark said it is planning to hold a press conference about the motion by the Justice Department on June 5. Court filings show two attorneys who helped file the initial complaint against Lakeland, Michael Campion and Susan Millenky, withdrew as counsel from the case. Campion was appointed in 2022 to lead the U.S. Attorney's Office's Civil Rights Division that was created to enforce federal civil rights laws in New Jersey. The Fair Housing Act was passed as part of the Civil Rights Act of 1968 to prohibit landlords and mortgage lenders from discriminating based on race, religion, national origin or sex. Nearly 60 years later, racial wealth disparity remains vast. In New Jersey, the median household wealth of white families is $322,500, compared with $17,700 for Black families and $26,100 for Hispanic families, the New Jersey Institute for Social Justice said. In New Jersey, 77.3% of white residents owned a home in 2020. By comparison, 42.8% of Black residents and 32.7% of Hispanic residents were homeowners, according to the Urban Institute, a research group. Critics said the Justice Department's motion to drop the Lakeland settlement is a step by the Trump administration's bid to reverse diversity, equity and inclusion programs. David Troutt, a professor at Rutgers Law School in Newark, said the motion by the Justice Department to terminate the consent decree is part of a larger campaign by the department to rescind investigations and agreements involving anti-Black racism, while beginning investigations into what it deems 'illegal DEI.' 'The Trump administration's withdrawal from a federal consent decree without justification is an extraordinary act of endorsing racist practices and housing market manipulation,' Troutt said. 'For the very government that successfully enforced those borrowers' civil rights to now repudiate them sends a message unlike any we've seen since the federal government first endorsed redlining in the 1930s,' Troutt said. Lakeland isn't the only New Jersey bank that faced scrutiny under the Biden administration. Toms River-based OceanFirst Financial Corp. agreed to pay $14 million to subsidize mortgages, helping settle a lawsuit that alleged the bank violated federal discrimination laws. Since then, it has improved the rating given by federal bank regulators who oversee investments in underserved communities to 'outstanding.' The Justice Department hasn't filed a motion seeking to terminate the consent order with OceanFirst. But two attorneys who represented the U.S. in the initial complaint, Millenky and Nathan Shulock, have filed motions to withdraw from the case, according to the court docket. A combined 22 Provident and Lakeland branches closed in 2024 following the $1.3 billion merger creating a 'super community bank.' Each branch that closed was within roughly three miles of a nearby branch. Activists and opponents warned that the merger would mean fewer banking services would be available for underserved communities, such as people of color, the elderly and disabled. New Jersey Citizen Action applauded Provident for its continued commitment to the terms of the consent order. But the group said the Justice Department should continue to enforce it. 'When you actually terminate these consent orders, there's no deterrence, and it's basically telling financial institutions that the Department of Justice is going to be taking a hands-off approach to fair lending issues, to redlining,' New Jersey Citizen Action's Amirhamzeh said. Daniel Munoz covers business, consumer affairs, labor and the economy for and The Record. Email: munozd@ Twitter:@danielmunoz100 and Facebook Michael L. Diamond is a business reporter for the Asbury Park Press. He has been writing about the New Jersey economy and health care industry since 1999. He can be reached at mdiamond@ This article originally appeared on Feds seek to drop Lakeland Bank settlement over alleged redlining
Los Angeles Times
30 minutes ago
- Los Angeles Times
Trump formally asks Congress to claw back approved spending targeted by DOGE
WASHINGTON — The White House on Tuesday officially asked Congress to claw back $9.4 billion in already approved spending, taking funding away from programs targeted by Elon Musk's Department of Government Efficiency. It's a process known as 'rescission,' which requires President Donald Trump to get approval from Congress to return money that had previously been appropriated. Trump's aides say the funding cuts target programs that promote liberal ideologies. The request, if it passes the House and Senate, would formally enshrine many of the spending cuts and freezes sought by DOGE. It comes at a time when Musk is extremely unhappy with the tax cut and spending plan making its way through Congress, calling it on Tuesday a 'disgusting abomination' for increasing the federal deficit. White House budget director Russ Vought said more rescission packages and other efforts to cut spending could follow if the current effort succeeds. ' Here's what to know about the rescissions request: The request to Congress is unlikely to meaningfully change the troublesome increase in the U.S. national debt. Tax revenues have been insufficient to cover the growing costs of Social Security, Medicare and other programs. The Congressional Budget Office estimates the government is on track to spend roughly $7 trillion this year, with the rescission request equaling just 0.1% of that total. White House press secretary Karoline Leavitt told reporters at Tuesday's briefing that Vought would continue to cut spending, hinting that there could be additional efforts to return funds. 'He has tools at his disposal to produce even more savings,' Leavitt said. Vought said he can send up additional rescissions at the end of the fiscal year in September 'and if Congress does not act on it, that funding expires.' 'It's one of the reasons why we are not putting all of our expectations in a typical rescissions process,' he added. A spokesperson for the White House Office of Management and Budget, speaking on condition of anonymity to preview some of the items that would lose funding, said that $8.3 billion was being cut from the State Department and the U.S. Agency for International Development. NPR and PBS would also lose federal funding, as would the U.S. President's Emergency Plan for AIDS Relief, also known as PEPFAR. The spokesperson listed specific programs that the Trump administration considered wasteful, including $750,000 to reduce xenophobia in Venezuela, $67,000 for feeding insect powder to children in Madagascar and $3 million for circumcision, vasectomies and condoms in Zambia. House Speaker Mike Johnson, R-La., complimented the planned cuts and pledged to pass them. 'This rescissions package reflects many of DOGE's findings and is one of the many legislative tools Republicans are using to restore fiscal sanity,' Johnson said. 'Congress will continue working closely with the White House to codify these recommendations, and the House will bring the package to the floor as quickly as possible.' Members of the House Freedom Caucus, among the chamber's most conservative lawmakers, said they would like to see additional rescission packages from the administration. 'We will support as many more rescissions packages the White House can send us in the coming weeks and months,' the group said in a press release. Sen. Susan Collins, chair of the Senate Appropriations Committee, gave the package a less optimistic greeting. 'Despite this fast track, the Senate Appropriations Committee will carefully review the rescissions package and examine the potential consequences of these rescissions on global health, national security, emergency communications in rural communities, and public radio and television stations,' the Maine lawmaker said in a statement. Boak writes for the Associated Press.
Yahoo
31 minutes ago
- Yahoo
Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
FREMONT, Calif., June 03, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates. The results were presented yesterday by Jyoti Mayadev, MD, from the University of California San Diego, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled "Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses." The results from this study were also simultaneously published in the journal Annals of Oncology. Samples were analyzed from patients with cervical cancer who had enrolled in the original CALLA clinical trial. In this new study analysis, NeXT Personal was used to look for small traces of ctDNA in blood samples from a cohort of 186 patients with locally advanced cervical cancer. Dr. Mayadev's team found that overall ctDNA levels after chemoradiotherapy (CRT) treatment were strongly predictive of risk of cervical cancer progression. "Despite standard chemoradiotherapy, up to half of patients with locally advanced cervical cancer relapse, underscoring the urgent need for better prognostic tools. In the CALLA phase 3 study, ultrasensitive, tumor-informed ctDNA analysis emerged as a powerful predictor of progression and survival—detecting relapse up to ~16 months before imaging. These findings highlight ctDNA's potential to guide treatment decisions and personalize care in high-risk cervical cancer," said Dr. Mayadev. Key findings presented: Detection of ctDNA following CRT was independently prognostic of patient outcomes. Risk of progression and death were at least 95% lower for patients where ctDNA was not detected ~3 months after completing CRT. Detection of ctDNA after CRT was associated with high subsequent risk of disease progression, and was detected a median of ~5 months and up to ~16 months earlier than by imaging scans. High ctDNA levels (≥ median) at baseline was associated with higher risk of progression and death. "We are excited to see the results presented for NeXT Personal in this large phase 3 study in cervical cancer," said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at Personalis. "Cervical cancer is the fourth most common cancer for women globally, resulting in hundreds of thousands of deaths each year. The new results show the strong potential for an ultrasensitive MRD test like NeXT Personal to inform treatment for cervical cancer patients." About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor or predict a patient's response to therapy or risk of cancer recurrence, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by ASCO. View source version on Contacts Investors: Caroline Cornerinvestors@ 415-202-5678 Media Contact pr@
